{
  "extraction_metadata": {
    "timestamp": "2025-10-04T13:48:41.317277",
    "source_type": "clinical_guideline",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 9,
    "temperature": 0.1
  },
  "outcomes_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "AT",
      "Outcomes": "response rate, progression-free survival, diarrhoea, dilation, nausea, transaminase increase, creatinine increase, QTc time prolongation",
      "ChunksUsed": 6,
      "ContextTokens": 1293
    },
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "Outcomes": "overall survival, response rates, progression-free survival, adverse events, Karnofsky performance status, ECOG performance status",
      "ChunksUsed": 2,
      "ContextTokens": 346
    },
    "DK": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DK",
      "Outcomes": "objective response rate, progression-free survival, diarrhoea, alanine aminotransferase increase, aspartate aminotransferase increase, neutropenia, fatigue, febrile neutropenia",
      "ChunksUsed": 8,
      "ContextTokens": 1732
    },
    "EN": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EN",
      "Outcomes": "overall survival, progression-free survival, health-related quality of life, objective response rate (RECIST 1.1), adverse events, EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D-5L",
      "ChunksUsed": 12,
      "ContextTokens": 2473
    },
    "ES": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "ES",
      "Outcomes": "",
      "ChunksUsed": 1,
      "ContextTokens": 252
    },
    "EU": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EU",
      "Outcomes": null,
      "ChunksUsed": 1,
      "ContextTokens": 159
    },
    "FR": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "FR",
      "Outcomes": "serious side effects on the skin",
      "ChunksUsed": 7,
      "ContextTokens": 1682
    },
    "NL": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "NL",
      "Outcomes": "progression free survival, quality of life, overall survival, objective response rate, adverse events",
      "ChunksUsed": 4,
      "ContextTokens": 835
    },
    "SE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "SE",
      "Outcomes": "symptom control, preservation of quality of life, prolonged survival",
      "ChunksUsed": 4,
      "ContextTokens": 812
    }
  }
}